A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

October 13, 2023

Study Completion Date

October 19, 2023

Conditions
Type 1 Diabetes Mellitus With Hypoglycemia
Interventions
COMBINATION_PRODUCT

VC-02 Combination Product

PEC-01 cells loaded into a Delivery Device

Trial Locations (10)

21205

Johns Hopkins University, Baltimore

43203

Ohio State University, Columbus

55455

University of Minnesota, Minneapolis

91010

City of Hope National Medical Center, Duarte

92121

University of California San Diego, San Diego

92697

UCLA-UCI Alpha Stem Cell Clinic, Irvine

95817

UC Davis - Alpha Stem Cell Clinic, Sacramento

Unknown

University Hospital Brussels, Brussels

University of Alberta, Edmonton

University of British Columbia, Vancouver

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

collaborator

Horizon 2020 - European Commission

OTHER

collaborator

Vertex Pharmaceuticals Incorporated

INDUSTRY

lead

ViaCyte

INDUSTRY